IL156272A - Method of determining the level of ercc1 gene expression and use of chemotherapeutic regimen selected by a method in the preparation of a medicament - Google Patents

Method of determining the level of ercc1 gene expression and use of chemotherapeutic regimen selected by a method in the preparation of a medicament

Info

Publication number
IL156272A
IL156272A IL156272A IL15627203A IL156272A IL 156272 A IL156272 A IL 156272A IL 156272 A IL156272 A IL 156272A IL 15627203 A IL15627203 A IL 15627203A IL 156272 A IL156272 A IL 156272A
Authority
IL
Israel
Prior art keywords
ercc1
medicament
level
preparation
determining
Prior art date
Application number
IL156272A
Other languages
Hebrew (he)
Original Assignee
Response Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/796,491 external-priority patent/US6518416B1/en
Application filed by Response Genetics Inc filed Critical Response Genetics Inc
Publication of IL156272A publication Critical patent/IL156272A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to prognostic methods which are useful in medicine, particularly cancer chemotherapy. The object of the invention to provide a method for assessing ERCC1 expression levels in fixed or fixed and paraffin embedded tissues and determine a platinum-based chemotherapy by examination of the amount of ERCC1 mRNA in a patient's tumor cells and comparing it to a predetermined threshold expression level. More specifically, the invention provides to oligonucleotide primer pair ERCC1 and methods comprising their use for detecting levels of ERCC1 mRNA.
IL156272A 2000-12-01 2003-06-02 Method of determining the level of ercc1 gene expression and use of chemotherapeutic regimen selected by a method in the preparation of a medicament IL156272A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US25012100P 2000-12-01 2000-12-01
US25047000P 2000-12-04 2000-12-04
US09/796,491 US6518416B1 (en) 2000-12-01 2001-03-02 Method of determining a chemotherapeutic regimen based on ERCC1 expression
US09/877,095 US6573052B2 (en) 2000-12-01 2001-06-11 Method of determining a chemotherapeutic regimen based on ERCCI expression
US09/988,784 US6602670B2 (en) 2000-12-01 2001-11-20 Method of determining a chemotherapeutic regimen based on ERCC1 expression
PCT/US2001/044519 WO2002061128A2 (en) 2000-12-01 2001-11-29 Method of determining a chemotherapeutic regimen based on ercc1 expression

Publications (1)

Publication Number Publication Date
IL156272A true IL156272A (en) 2013-12-31

Family

ID=45773848

Family Applications (2)

Application Number Title Priority Date Filing Date
IL156272A IL156272A (en) 2000-12-01 2003-06-02 Method of determining the level of ercc1 gene expression and use of chemotherapeutic regimen selected by a method in the preparation of a medicament
IL215130A IL215130A0 (en) 2000-12-01 2011-09-13 Method of determining a chemotherapeutic regimen based on ercci expression

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL215130A IL215130A0 (en) 2000-12-01 2011-09-13 Method of determining a chemotherapeutic regimen based on ercci expression

Country Status (14)

Country Link
US (2) US6602670B2 (en)
EP (1) EP1364054B1 (en)
JP (1) JP4503922B2 (en)
KR (1) KR100966271B1 (en)
CN (1) CN1636069B (en)
AR (1) AR031455A1 (en)
AU (1) AU2002249768B2 (en)
CA (1) CA2437044C (en)
ES (1) ES2439873T3 (en)
HK (1) HK1078328A1 (en)
IL (2) IL156272A (en)
MX (1) MXPA03004930A (en)
NZ (1) NZ526710A (en)
WO (1) WO2002061128A2 (en)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003534292A (en) * 2000-05-19 2003-11-18 ジェネンテック・インコーポレーテッド ERBB antagonist gene detection assays to increase the likelihood of effective response to cancer treatment
US6602670B2 (en) * 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US7049059B2 (en) * 2000-12-01 2006-05-23 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression
WO2003078662A1 (en) * 2002-03-13 2003-09-25 Genomic Health Gene expression profiling in biopsied tumor tissues
WO2004011625A2 (en) * 2002-07-31 2004-02-05 University Of Southern California Polymorphisms for predicting disease and treatment outcome
EP1572105B1 (en) 2002-11-14 2011-08-31 John Wayne Cancer Institute Detection of micro metastasis of melanoma and breast cancer in paraffin-embedded tumor draining lymph nodes by multimaker quantitative rt-pcr
US8039218B2 (en) * 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
AU2003295598B2 (en) * 2002-11-15 2009-12-24 Genomic Health, Inc. Gene expression profiling of EGFR positive cancer
US8580498B2 (en) * 2002-11-15 2013-11-12 University Of South Florida Predictive value of nuclear excision repair genes for cancer survival
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
WO2004071572A2 (en) * 2003-02-06 2004-08-26 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
ATE412779T1 (en) * 2003-02-20 2008-11-15 Genomic Health Inc USE OF INTRONIC RNA SEQUENCES TO QUANTIFY GENE EXPRESSION
CA2527285A1 (en) * 2003-05-28 2004-12-23 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
JP2007506442A (en) * 2003-05-30 2007-03-22 ゲノミック ヘルス， インコーポレイテッド Gene expression markers for response to EGFR inhibitors
ES2787475T3 (en) 2003-06-24 2020-10-16 Genomic Health Inc Prediction of probability of cancer recurrence
ES2905579T3 (en) * 2003-07-10 2022-04-11 Genomic Health Inc Expression profiling algorithm and test for prognosis of breast cancer relapse
US20050196782A1 (en) * 2003-12-23 2005-09-08 Kiefer Michael C. Universal amplification of fragmented RNA
EP2947160B1 (en) 2004-04-09 2017-07-12 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
US20060115827A1 (en) * 2004-07-01 2006-06-01 University Of Southern California Genetic markers for predicting disease and treatment outcome
ATE550440T1 (en) 2004-11-05 2012-04-15 Genomic Health Inc MOLECULAR INDICATORS FOR BREAST CANCER PROGNOSIS AND PREDICTION OF TREATMENT RESPONSE
AU2005304824B2 (en) * 2004-11-05 2011-12-22 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
KR20130089280A (en) 2005-01-21 2013-08-09 제넨테크, 인크. Fixed dosing of her antibodies
CA2595395A1 (en) * 2005-02-09 2006-08-17 Genentech, Inc. Inhibiting her2 shedding with matrix metalloprotease antagonists
MY152164A (en) 2005-02-23 2014-08-15 Genentech Inc Extending time to disease progression or survival in cancer patients
WO2006096861A2 (en) * 2005-03-08 2006-09-14 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
CN101218353A (en) * 2005-05-04 2008-07-09 南佛罗里达大学 Predicting treatment response in cancer subjects
JP2006316040A (en) 2005-05-13 2006-11-24 Genentech Inc Herceptin(r) adjuvant treatment
EP1835285A1 (en) 2006-03-14 2007-09-19 Institut Gustave Roussy ERCC1 expression in predicting response for cancer chemotherapy
US9702875B2 (en) 2006-03-14 2017-07-11 Institute Gustave-Roussy Expression of isoform 202 of ERCC1 for predicting response to cancer chemotherapy
BRPI0808418A2 (en) 2007-03-02 2014-07-22 Genentech Inc PREDICTION OF RESPONSE TO A HER INHIBITOR
DK2171090T3 (en) * 2007-06-08 2013-06-10 Genentech Inc Gene expression markers for tumor resistance to HER2 inhibitor therapy
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
KR20100044780A (en) * 2007-06-15 2010-04-30 유니버시티 오브 사우스 플로리다 Methods of diagnosing and treating cancer
US20100273711A1 (en) * 2007-09-28 2010-10-28 Anil Potti Individualized cancer treatments
CN101140241B (en) * 2007-09-30 2010-11-03 浙江省肿瘤医院 Platinum kind anti-cancer drugs susceptibility related gene inspect reagent kit and applications thereof
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
US8632984B2 (en) * 2009-02-16 2014-01-21 Atlas Antibodies Ab RBM3 as a marker for malignant melanoma prognosis
CN102356092B (en) 2009-03-20 2014-11-05 霍夫曼-拉罗奇有限公司 Bispecific anti-HER antibodies
EP2435071A1 (en) 2009-05-29 2012-04-04 F. Hoffmann-La Roche AG Modulators for her2 signaling in her2 expressing patients with gastric cancer
RU2587619C2 (en) 2010-02-18 2016-06-20 Дженентек, Инк. Neuregulin antagonists and use thereof in treating malignant growth
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
JP5769952B2 (en) * 2010-11-12 2015-08-26 株式会社Ｌｓｉメディエンス Highly sensitive detection method for EML4-ALK fusion gene
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
WO2012076582A1 (en) * 2010-12-09 2012-06-14 F. Hoffmann-La Roche Ag Agtr1 as a marker for bevacizumab combination therapies
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
US9626650B2 (en) 2011-04-14 2017-04-18 Elwha Llc Cost-effective resource apportionment technologies suitable for facilitating therapies
US10445846B2 (en) 2011-04-14 2019-10-15 Elwha Llc Cost-effective resource apportionment technologies suitable for facilitating therapies
US8514067B2 (en) 2011-08-16 2013-08-20 Elwha Llc Systematic distillation of status data relating to regimen compliance
EP2744824A1 (en) 2011-08-17 2014-06-25 F.Hoffmann-La Roche Ag Neuregulin antibodies and uses thereof
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
SG11201402510TA (en) 2011-11-30 2014-06-27 Genentech Inc Erbb3 mutations in cancer
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
US10528913B2 (en) 2011-12-30 2020-01-07 Elwha Llc Evidence-based healthcare information management protocols
US10475142B2 (en) 2011-12-30 2019-11-12 Elwha Llc Evidence-based healthcare information management protocols
US10340034B2 (en) 2011-12-30 2019-07-02 Elwha Llc Evidence-based healthcare information management protocols
US10552581B2 (en) 2011-12-30 2020-02-04 Elwha Llc Evidence-based healthcare information management protocols
US10559380B2 (en) 2011-12-30 2020-02-11 Elwha Llc Evidence-based healthcare information management protocols
US20130173294A1 (en) 2011-12-30 2013-07-04 Elwha LLC, a limited liability company of the State of Delaware Evidence-based healthcare information management protocols
US10679309B2 (en) 2011-12-30 2020-06-09 Elwha Llc Evidence-based healthcare information management protocols
EP2831115A1 (en) 2012-03-27 2015-02-04 F. Hoffmann-La Roche AG Diagnosis and treatments relating to her3 inhibitors
CN102676661B (en) * 2012-04-27 2014-12-31 中国人民解放军第四军医大学 Fluorescent polarization based homogeneous phase detection method of single nucleotide polymorphism of codon118 of ERCC1 (excision repair cross-complementing 1) gene
CA2874035C (en) * 2012-05-22 2021-11-09 The Johns Hopkins University A quantitative multiplex methylation specific pcr method- cmethdna, reagents, and its use
JP6998646B2 (en) 2012-11-30 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Identification of patients in need of PD-L1 inhibitor combination therapy
EP3014505A4 (en) * 2013-06-28 2017-03-08 Nantomics, LLC Pathway analysis for identification of diagnostic tests
GB201316024D0 (en) * 2013-09-09 2013-10-23 Almac Diagnostics Ltd Molecular diagnostic test for lung cancer
CN103451303B (en) * 2013-09-12 2015-02-11 江苏康克生物技术有限公司 Kit for detecting expression level of human ERCC1 (excision repair cross complementation 1) through PCR (polymerase chain reaction) method
CN105219881B (en) * 2015-11-17 2018-11-20 东南大学 The kit of quantitative detection ERCC1-202 a kind of and application
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer
US20190338363A1 (en) * 2016-12-18 2019-11-07 Selonterra, Inc. Use of apoe4 motif-mediated genes for diagnosis and treatment of alzheimer's disease
AU2018289369A1 (en) * 2017-06-20 2020-01-16 Nantomics, Llc Use of cell-free circulating rna (cfRNA) expression of PD-L1 and ERCC1 in plasma to monitor response to therapy in NSCLC

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4830969A (en) 1981-08-31 1989-05-16 The Research Foundation Of State University Of New York Process for the rapid and simple isolation of nucleic acids
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US5128247A (en) 1989-08-14 1992-07-07 Board Of Regents, The University Of Texas System Methods for isolation of nucleic acids from eukaryotic and prokaryotic sources
US5284940A (en) 1990-11-14 1994-02-08 Hri Research, Inc. Preparation for nucleic acid samples
US5654179A (en) 1990-11-14 1997-08-05 Hri Research, Inc. Nucleic acid preparation methods
US5620852A (en) 1990-11-14 1997-04-15 Hri Research, Inc. Nucleic acid preparation methods
JP3171863B2 (en) * 1991-01-16 2001-06-04 伊藤製油株式会社 Amphoteric surfactant composition
US5346994A (en) 1992-01-28 1994-09-13 Piotr Chomczynski Shelf-stable product and process for isolating RNA, DNA and proteins
US5502166A (en) 1992-02-26 1996-03-26 Mitsubishi Chemical Corporation NMDH receptor proteins and genes encoding the same
JP3615545B2 (en) 1993-02-01 2005-02-02 キアゲン・エヌ・ブイ Quaternary ammonium salt surfactant and its RNA isolator
US5637687A (en) 1993-08-31 1997-06-10 Wiggins; James C. Methods and compositions for isolating nucleic acids
WO1995028489A1 (en) 1994-04-13 1995-10-26 The Uab Research Foundation Dihydropyrimidine dehydrogenase compositions and methods of use
US5643767A (en) 1994-05-02 1997-07-01 The Rockefeller University Process for isolating cellular components
JP3125633B2 (en) * 1994-07-06 2001-01-22 和光純薬工業株式会社 Method and kit for processing paraffin-embedded tissue specimen as sample for gene analysis
CA2153215A1 (en) 1994-07-06 1996-01-07 Lu Wang Treatment of paraffin embedded tissue for gene analysis
US5707802A (en) 1995-01-13 1998-01-13 Ciba Corning Diagnostics Corp. Nucleic acid probes for the detection and identification of fungi
US5777099A (en) 1995-02-24 1998-07-07 Biotecx Laboratories, Inc. RNA separation
US5705336A (en) * 1995-03-07 1998-01-06 The United States Of America As Represented By The Department Of Health And Human Services Assay for sensitivity of tumors to DNA-platinating chemotherapy
US5945515A (en) 1995-07-31 1999-08-31 Chomczynski; Piotr Product and process for isolating DNA, RNA and proteins
DE29601618U1 (en) 1996-01-31 1996-07-04 InViTek GmbH, 13125 Berlin Multiple simultaneous isolation device
EP0791654A1 (en) 1996-02-21 1997-08-27 Jürgen A. Dr. Richt Polypeptides corresponding to the amino acid sequences of proteins p57 or p9.5 of Borna disease virus, nucleic acid fragments coding therefore and their use for diagnostic and immunization purposes
CA2249364C (en) 1996-03-20 2009-07-07 Frank J. Gonzalez Methods and compositions for detecting dihydropyrimidine dehydrogenase splicing mutations
EP0912726A4 (en) 1996-05-10 2001-07-18 Phylomed Corp Methods for oxidizing disulfide bonds using ozone
AU6764398A (en) 1997-03-20 1998-10-12 Variagenics, Inc. Target genes for allele-specific drugs
US5994076A (en) 1997-05-21 1999-11-30 Clontech Laboratories, Inc. Methods of assaying differential expression
ES2313752T3 (en) 1997-08-20 2009-03-01 The University Of Miami A METHOD OF FIXATION-DEHYDRATION-ELIMINATION OF FAT-IMPREGNATION OF CONTINUOUS PRODUCTION FABRICS, OF HIGH QUALITY.
US5952202A (en) 1998-03-26 1999-09-14 The Perkin Elmer Corporation Methods using exogenous, internal controls and analogue blocks during nucleic acid amplification
US6204375B1 (en) 1998-07-31 2001-03-20 Ambion, Inc. Methods and reagents for preserving RNA in cell and tissue samples
US6248535B1 (en) 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
US6602670B2 (en) * 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US7049059B2 (en) * 2000-12-01 2006-05-23 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression

Also Published As

Publication number Publication date
WO2002061128A2 (en) 2002-08-08
ES2439873T3 (en) 2014-01-27
WO2002061128A3 (en) 2003-09-25
EP1364054B1 (en) 2013-09-25
HK1078328A1 (en) 2006-03-10
EP1364054A2 (en) 2003-11-26
US20040005621A1 (en) 2004-01-08
US7132238B2 (en) 2006-11-07
IL215130A0 (en) 2011-10-31
JP2004518429A (en) 2004-06-24
AR031455A1 (en) 2003-09-24
CN1636069B (en) 2012-03-07
JP4503922B2 (en) 2010-07-14
AU2002249768B2 (en) 2007-01-04
KR20030074639A (en) 2003-09-19
US6602670B2 (en) 2003-08-05
CA2437044A1 (en) 2002-08-08
KR100966271B1 (en) 2010-06-28
CN1636069A (en) 2005-07-06
CA2437044C (en) 2013-03-12
US20020086315A1 (en) 2002-07-04
NZ526710A (en) 2005-09-30
MXPA03004930A (en) 2005-06-06

Similar Documents

Publication Publication Date Title
IL156272A (en) Method of determining the level of ercc1 gene expression and use of chemotherapeutic regimen selected by a method in the preparation of a medicament
TW200628614A (en) Methods for determining a chemotherapeutic regimen comprising 5-fluorouracil, oxaliplatin, or combination thereof for treating a tumor in a patient
TW200833846A (en) Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival
HK1070921A1 (en) Method for determining the expression level of glutathione-s-transferase pi
WO2002070750A3 (en) Method of determining dihydropyrimidine dehydrogenase gene expression
ES2562078T3 (en) Methods and compositions for inducing deregulation of phosphorylation of EphA7 and ERK in acute human leukemia
Nie et al. Overexpression of stathmin 1 is a poor prognostic biomarker in non-small cell lung cancer
Guo et al. Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib
TW200512298A (en) Method of diagnosing breast cancer
Jandova et al. Genomic GLO1 deletion modulates TXNIP expression, glucose metabolism, and redox homeostasis while accelerating human A375 malignant melanoma tumor growth
AU2012342397B2 (en) A method for predicting responsiveness to a treatment with an EGFR inhibitor
ES2742840T3 (en) Micro-RNA biomarkers to identify risk and / or diagnose lung tumor
Palisoul et al. Identification of molecular targets in vulvar cancers
Cashman et al. SENP5 mediates breast cancer invasion via a TGFβRI SUMOylation cascade
CN106662543A (en) Non-invasive gene mutation detection in lung cancer patients
Spindler et al. Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region
MXPA06014175A (en) Diagnosing or predicting the course of breast cancer.
Miyoshi et al. ATP11A is a novel predictive marker for metachronous metastasis of colorectal cancer
ES2319891T3 (en) FACTOR INVOLVED IN THE METASTASIS AND USES OF THE SAME.
Noske et al. Combination of p53 expression and p21 loss has an independent prognostic impact on sporadic colorectal cancer
ES2937269T3 (en) Synthetic lethality and cancer treatment
André et al. Current status of adjuvant therapy for colon cancer
Xian et al. High APRIL expression correlates with unfavourable survival of gastrointestinal stromal tumour
ES2377062T3 (en) Methods to determine a chemotherapeutic regimen based on the loss of heterozygosity in the thymidylate synthase locus
Apanovich et al. Expression Profiles of Genes—Potential Therapy Targets—and Their Relationship to Survival in Renal Cell Carcinoma

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees